In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations

Rodolfo A Estrada; Diego J Maselli; Antonio R Anzueto

doi:10.7326/J23-0063

In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations

Ann Intern Med. 2023 Sep;176(9):JC102. doi: 10.7326/J23-0063. Epub 2023 Sep 5.

Authors

Rodolfo A Estrada¹, Diego J Maselli¹, Antonio R Anzueto¹

Affiliation

¹ UT Health San Antonio, San Antonio, Texas, USA (R.A.E., D.J.M., A.R.A.).

PMID: 37665985
DOI: 10.7326/J23-0063

Abstract

Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389;205-214.37272521.

Publication types

Comment

MeSH terms

Administration, Inhalation
Bronchodilator Agents*
Humans
Inflammation
Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

dupilumab
Bronchodilator Agents